| Literature DB >> 35335634 |
Piotr Bąska1, Luke J Norbury2.
Abstract
The immune system consists of various cells, organs, and processes that interact in a sophisticated manner to defend against pathogens. Upon initial exposure to an invader, nonspecific mechanisms are raised through the activation of macrophages, monocytes, basophils, mast cells, eosinophils, innate lymphoid cells, or natural killer cells. During the course of an infection, more specific responses develop (adaptive immune responses) whose hallmarks include the expansion of B and T cells that specifically recognize foreign antigens. Cell to cell communication takes place through physical interactions as well as through the release of mediators (cytokines, chemokines) that modify cell activity and control and regulate the immune response. One regulator of cell states is the transcription factor Nuclear Factor kappa B (NF-κB) which mediates responses to various stimuli and is involved in a variety of processes (cell cycle, development, apoptosis, carcinogenesis, innate and adaptive immune responses). It consists of two protein classes with NF-κB1 (p105/50) and NF-κB2 (p100/52) belonging to class I, and RelA (p65), RelB and c-Rel belonging to class II. The active transcription factor consists of a dimer, usually comprised of both class I and class II proteins conjugated to Inhibitor of κB (IκB). Through various stimuli, IκB is phosphorylated and detached, allowing dimer migration to the nucleus and binding of DNA. NF-κB is crucial in regulating the immune response and maintaining a balance between suppression, effective response, and immunopathologies. Parasites are a diverse group of organisms comprised of three major groups: protozoa, helminths, and ectoparasites. Each group induces distinct effector immune mechanisms and is susceptible to different types of immune responses (Th1, Th2, Th17). This review describes the role of NF-κB and its activity during parasite infections and its contribution to inducing protective responses or immunopathologies.Entities:
Keywords: NF-κB; RelA; immune response; p50; p65; parasites
Year: 2022 PMID: 35335634 PMCID: PMC8950322 DOI: 10.3390/pathogens11030310
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Figure 1Schematic model of NF-κB activation through canonical and non-canonical pathways. Canonical activation involves TGF-β activated kinase-1 (TAK1) which phosphorylates Inhibitory Kappa B Kinase β (IKKβ) complexed with IKKα and IKKγ (NEMO). This leads to phosphorylation of the α Inhibitor of κB (IκBα), its detachment from the p56/p50 dimer, ubiquitination, and proteasomal degradation. Released p65/p50 dimer migrates to the nucleus and binds to DNA sequences leading to transcription of appropriate genes. During the noncanonical pathway, NF-κB-inducing kinase (NIK) phosphorylates the IKKα dimer which phosphorylates p100 leading to its disruption and release of the RelB/p52 dimer. The dimer migrates to the nucleus and regulates the transcription of particular genes.
Figure 2The impact of Plasmodium spp., Trypanosoma cruzi, Toxoplasma gondii, and Leishmania spp. on NF-κB activity and outcomes. (A) Plasmodium spp. increase NF-κB activity in specific cell populations which is associated with pathology in the brain, inducing cerebral malaria symptoms (apoptosis in brain endothelial cells and intravascular leukocytes), and may facilitate hidden parasite populations in the spleen. Plasmodium spp. also trigger an inflammatory response in monocytes, but patients with decreased NF-κB activity in PBMCs show more severe malaria symptoms. (B) Reduced NF-κB activity facilitates infection of T. cruzi. Enhanced NF-κB activity in heart tissue during T. cruzi infections leads to heart failure. (C) RelB-deprived mice do not survive T. gondii infection. T. gondii deactivate NF-κB signaling, reducing the immune response in macrophages and neutrophils. (D) Leishmania spp. reduce NF-κB activity in infected macrophages and DC, facilitating parasite survival.
Figure 3The impact of helminths on NF-κB activity and outcomes. (A) B. malayi infection results in decreased NF-κB activity and induces M2 and eventually Mreg macrophages, while patients with lymphatic pathology show increased angiogenesis associated with NF-κB activation. H. polygyrus induces semi-maturation of DCs and induces Th2 and regulatory events through modulation of NF-κB activity. Products released by T. spiralis affect NF-κB activity in LPS-activated macrophages, significantly reducing proinflammatory cytokine production. (B) T. solium larval antigens activate the NF-κB pathway in monocytes inducing chemokine release. M. corti antigens inhibit LPS-induced inflammatory phenotypes in microglia cells via NF-κB modulation. (C) F. hepatica tegumental antigens temporarily prevent LPS-induced NF-κB in DC, suppressing maturation. S. mansoni induces NF-κB activation in human hepatic stellate cells which is associated with liver fibrosis; a similar situation occurs in S. Japonicum-infected mice.
Plasmodium spp. impact on NF-κB activity and outcomes.
| Parasite | Infection/Life Stage/Antigen | Host/Location/Model | Effect on NF-κB | Outcome |
|---|---|---|---|---|
|
Trophozoites Haemozoin | Human monocytes | Translocation of p65, p50 to nucleus of monocytes; degradation of IκBα. | Enhanced activity of MMP-9, enhanced production of proinflammatory cytokines TNF and IL-1β. | |
|
Infected human patients | Peripheral blood mononuclear cells | Elevated phospho-NF-κB p65 levels ( | Possible association of lower NF-κB features in patients with complicated | |
|
Fatal cases of human cerebral malaria | Brain tissue | Increase in expression of nuclear NF-κB p65 in the brain (neurons, glial cells, ECs, and intravascular leukocytes). | NF-κB p65 levels correlate with histopathological changes (apoptosis) in brain. NF-κB p65 modulates apoptosis in the brain endothelial cells and intravascular leukocytes (but not glial cells, neurons) of fatal cerebral malaria patients. | |
|
Plasma-derived extracellular vesicles from | Human spleen fibroblasts | Translocation of NF-κB to the nucleus. | Upregulation of ICAM-1 surface expression, facilitating adhesion of infected reticulocytes. | |
|
Trophozoite-stage | Human brain microvascular endothelial cells | Upregulation of NF-κB activation cascade, upregulation of NF-κB subunits (p100, p105, cREL, RELB) and upregulation of NF-κB inhibitory proteins (IκBα, IκBε). Increased p65 translocation to nucleus. | Increased proinflammatory cytokine release (CCL20 and TNF-α). | |
|
Infected patients | Liver tissue | p65 expression in B cells and Kupffer cells correlates with severity of the disease. | Apoptosis of Kupffer cells and portal tract lymphocytes is related to NF-κB activation. | |
|
Trophozoite-stage | Human brain microvascular endothelial cells | Induction of nuclear translocation of NF-κB (p65). | Increase in ICAM-1 surface expression. |
Trypanosoma spp. impact on NF-κB activity and outcomes.
| Parasite | Infection/Life Stage/Antigen | Host/Location/Model | Effect on NF-κB | Outcome |
|---|---|---|---|---|
|
Trypomastigotes | Primary human colon epithelial cells | Increase in p65 and IKKα/β phosphorylation, increase in phosphorylation of NF-κB upstream regulators (TAK1 and IRAK4). | Modulated expression of NF-κB signaling molecules, proposed to promote pro-inflammatory signaling pathways. | |
|
Soluble | Mouse macrophages | Increased phosporylation of NF-κB p65 (partially dependent on MGL1 receptor). | IL-10, TNF-α, and nitric oxide (NO) production. | |
|
Experimental infection | Thoracic aortic rings from infected C57BL/6 mice | Increase in expression of NF-κB p65. | Increased expression of COX-2 and thromboxane synthase in aortas leading to vascular contraction. | |
|
Mouse infection with tripomastigotes, Sialidases Trans-sialidases | Bovine aortic endothelial cells, in vivo experiments | Translocation of NF-κB to nucleus, IκBα phosphorylation, NF-κB activation via classical pathway (mediated by parasite trans-sialidase). | Endothelial cell activation, and subsequent pro-inflammatory response–production of cytokines IL-1β and IL-6, nitric oxide and | |
|
Trypomastigotes | Human cardiomyocytes (AC16) | Increased nuclear translocation of p65, enhanced expression of NF-κB dependent genes. | Enhanced mRNA expression of TNF-α and IL-β. | |
|
Trypomastigotes | Mink lung epithelial cells (Mv1lu), murine endothelial line (SVEC4–10), primary cultures of human fibroblasts, rat myoblasts (L6E9 and H9c2), primary human vascular smooth muscle cells, bovine aortal muscle cells | Nuclear translocation of p65 in epithelial cells, endothelial cells, and fibroblasts, enhanced expression of NF-κB dependent genes. | NF-κB activation by parasites limits infection levels whereas experimental blocking of NF-κB signaling increases parasite burden. | |
|
Trypomastigotes | Human umbilical vein endothelial cells (HUVEC) | Nuclear translocation of active NF-κB (p65 and p50). | Induction of vascular cell adhesion molecule 1 (VCAM-1) and E-selectin and the upregulation of intercellular adhesion molecule 1 (ICAM-1). | |
|
Wild Cruzain-deficient | J774 macrophages | Proteolytic cleavage of NF-κB p65 by cruzain. | Impairment of macrophage activation pathways (reduced IL-12, increased L-arginase). |
Toxoplasma gondi impact on NF-κB activity and outcomes.
| Parasite | Infection/Life Stage/Antigen | Host/Location/Model | Effect on NF-κB | Outcome |
|---|---|---|---|---|
|
Tachyzoites | Mouse primary peritoneal macrophages | Phosphorylation of p65 through downregulation of miR-187. | Delayed production of IL-12. | |
|
Dense granule protein GRA16 | Human Non-Small Cell Lung Cancer H1299 cells deficient in p53 | GRA16 prevents NF-κB activation; decreased total and nuclear levels of p65, decreased IKKβ level, decreased phosphorylation of IkBα. | Decrease in cell survival, induce cell apoptosis. | |
|
Tachyzoites | Human neutrophils | Reduction in LPS-induced IκBα degradation and p65 phosphorylation. | Reduction in release of LPS induced IL-1β. | |
|
Tachyzoites of virulent & avirulent strains | In vivo: mice. | Virulent strain resulted in less p65 translocation to the nucleus and IκBα phosphorylation compared to avirulent strain. | Avirulent strains induced increased TNF-α and IL-12 release compared to virulent strains. Avirulent and virulent strain polarized macrophages towards M1 and M2 phenotypes, respectively. | |
|
Tachyzoites of virulent strain | Human foreskin fibroblasts, NIH 3T3 fibroblasts, MEF, HeLa, and COS cell lines, as well as primary cultures of mouse and human macrophages | Lack of nuclear p65/RelA translocation despite IκB degradation. No increase in expression of NF-κB dependent genes upon infection. | The results show that | |
|
Tachyzoites of virulent strain | Mouse bone marrow-derived macrophages | Inhibition of LPS-induced NF-κB translocation. | Blocked production of proinflammatory TNF-α and delayed (24 h) IL-12 in response to LPS. | |
|
Tachyzoites of virulent strain | In vivo: mice. | In vivo: activation of NF-κB, higher expression of p65, p50 from 24 h. | In vitro: reduced capacity to increase transcription of IL-12, IL-18, and iNOS in response to LPS and IFN-γ. | |
|
in vitro infection | 3T3 mouse embryonic fibroblasts, 3T3 p65−/− fibroblasts | nuclear translocation of p50 and p65. Higher affinity to DNA for p50, p52, p65, and RelB. Phosphorylation but no IκB degradation. | Upregulation of antiapoptotic responses. | |
|
| Human foreskin fibroblast, RAW264.7 (mouse macrophage cell line), U937 (human macrophage cell line) | ROP18+ strain induced p65 phosphorylation at Ser468 and promotes its degradation. | ROP18+: reduced LPS-induced IL-6, IL-12, and TNF-α; M2-biased phenotypes. | |
|
Tachyzoites | Mouse bone marrow-derived macrophages | No change in LPS induced p65 accumulation in nucleus as well as NF-kB binding to DNA. Significant diminished ability of p65 to bind to TNF-α promoter. | Describes | |
|
Tachyzoites of type I, II and III | Primary human monocytes and THP-1 cells | Type II: increased p65 accumulation in nucleus. | Type II: expression of IL-1β. | |
|
Tachyzoites | Primary human peripheral blood monocytes | Increase in phosphorylation of p65. | Expression of IL-1β. | |
|
Cysts | Wild type and RelB−/− C57B6 mice. | Infection induces NF-κB DNA binding activities of p65 and RelB containing complexes in the spleen. | RelB−/− mice show high mortality in response to the infection with negligible levels of IFN-γ and diminished NK cell activity. | |
|
Tachyzoites | In vivo: Mice (injected intra peritoneally with tachyzoites). | In vivo: no NF-κB translocation in macrophages or neutrophils within 4h of infection. | In vitro: little or no production of IL-12 and TNF-α; LPS triggering unable to promote IL-12 and TNF-α production. |
Leishmania spp. impact on NF-κB activity and outcomes.
| Parasite | Infection/Life Stage/Antigen | Host/Location/Model | Effect on NF-κB | Outcome |
|---|---|---|---|---|
|
Amastigotes | Promonocytic human cell line U937 and fresh human peripheral blood monocytes | Inhibition of DNA binding activity of p50/p65 heterodimer. Induction of | Increase in IL-10 and TNF-α secretion. | |
|
Amastigotes Amastigotes opsonized with antibiodies | murine immature bone marrow-derived DCs | Expression of p65 and RelB. | Alternative NF-κB pathway is favored, likely promoting MHC I-restricted antigen presentation. Amastigote infection does not change maturation status whereas antibody opsonized amastigotes induce semi-mature DC phenotype. | |
|
Promastigote extracellular vesicles | Murine peritoneal Macrophages, THP-1 macrophages | Only | Only | |
|
Amastigotes | Human THP-1 cells | Reduction of total p65 protein, lower expression of total Iκ-Bα protein, decrease in IkBα phosphorylation (Ser 32/36), no p65 cleavage to p35. | NF-κB signal pathway downregulation proposed to promote induction of apoptosis to facilitate spreading. | |
|
Promastigotes | Mouse macrophages and mouse macrophages with inhibited miR-210 expression | During the infection p50 and p65 expression relatively unchanged in cytoplasm and nucleus. During the infection and miR-210 inhibition increased p50/p65 translocation to nucleus. | Infection: marginally elevated TNF-α, IL-12, and IL-10. | |
|
Promastigotes | BM derived mouse macrophages | Infection did not inhibit NF-κB activation: no impact on p65 translocation, no impact on LPS-induced IκBα degradation, no activation of NF-κB dependent gene expression. | Infection inhibits LPS-induced IL-12 (not NF-κB related) | |
|
Promastigotes | Mouse bone marrow-derived DCs | Cleavage of p65 to p35, IκB-α phosphorylation and degradation unchanged. | Slightly increased expression of IL-12, unchanged IL-10, IL-6, TNF-α expression. Reduced LPS-induced IL-12 and IL-6, increased IL-10, TNF-α unchanged. | |
|
Promastigotes | B10R macrophage, primary bone marrow-derived macrophages, mouse and human macrophage cell lines Raw264.7, J774 and THP-1 | Excluding non-pathogenic | Induction of chemokine gene expression (MIP-2/CXCL2, MCP-1/CCL2, MIP-1a/CCL3, MIP-1b/CCL4). |
Cestodes impact on NF-κB activity and outcomes.
| Parasite | Infection/Life Stage/Antigen | Host/Location/Model | Effect on NF-κB | Outcome |
|---|---|---|---|---|
|
Product released by the parasite ( | Mouse BMDCc | Inhibition of DC maturation, cytokine production, and the ability of LPS-treated DCs to prime Th1 responses. | ||
|
Larval antigen ( | Human primary monocytes | Increased degradation of IkB-α but not IkBβ; increased DNA binding by p65, p50, and cRel. | Induced CCL2, CXCL8, and CCL3 secretion. | |
|
Helminth soluble factors (HSFs) | Mouse microglia cells | Decrease in LPS-induced p65 phosphorylation and acetylation. | Inhibition of LPS-induced secretion of IL-6 and TNF-α cytokines. | |
|
Fractionated Lewis sugars | Mouse spleen cells | p65 level increased, p50 level was not affected. | Release of IFN-γ from spleen cells stimulated with N glycans upon stimulation with |
Nematodes impact on NF-κB activity and outcomes.
| Parasite | Infection/Life Stage/Antigen | Host/Location/Model | Effect on NF-κB | Outcome |
|---|---|---|---|---|
|
Recombinant | Colitic mice | Changes in NF-κB signaling pathway. | Mitigation of colitis symptoms. | |
|
microfilarial sheath protein ( | Mouse macrophages (RAW 264.7) | Increased NF-κB phosphorylation | ||
|
Product released by the parasite ( | Colon epithelial cell line (CMT93) | Dynamic increase in p65 phosphorylation. Increase at 4 h post-exposure, back to baseline level by 24 h. | Increased release of proinflammatory factors IFN-γ, TNF, and CCL2. | |
|
Infection with | B6 mice and NF-κB1 KO, NF-κB2 KO, | Enhanced activity of NF-κB upon infection in B6 mice. | c-Rel KO mice: expelled worms and lymph node cells released low level of IFN-γ. NF-κB1 KO and NF-κB2 KO mice: unable to terminate infection, NF-κB1 KO mice lymph node cells released high levels of IFN-γ, and mice developed intestinal immunopathology. | |
|
newborn larvae (NBL) | Human macrophage cell line (U937) | Downregulation of NF-κB following P2X7R blockade. | Inhibits NLRP3 inflammasome activation and decreases macrophage capacity to kill | |
|
ES products of L1 muscle larvae | Mouse macrophages (RAW264.7) | Reduced LPS-induced p65 expression levels. | Increased regulatory IL-10, reduced LPS-induced proinflammatory (TNF-α and IL-12) and regulatory cytokines (IL-10). | |
|
ES of muscle larvae (ML) and adult worms (3 and 5-day-old) and newborn larvae (NBL) | Macrophage cell line (J774A.1) | Reduced LPS-induced p65 nuclear translocation. | Increased levels of anti-inflammatory cytokines (IL-10, TGF-β) and arginase 1, and (ML) iNOS. Reduced LPS-induced expression of proinflammatory (TNF-α, IL-1β, IL-6, IL-12) cytokines and (Ad3+Ad5+NBL) iNOS. | |
|
Experimental infection with | BALB/c mice | Expression downregulation for p65 and p50/105 in M2 macrophages and dramatic decrease in p65 and p50/105 in Mreg. | Alternatively activated (M2) and regulatory (Mreg) macrophages appeared 3 and 7 dpi, respectively. | |
|
Humans with lymphedema Humans with aspymptomatic infection | TLR ligands | Use of NF-κB inhibitor. | Diminished production of Angiopoetin-I and VEGF-A in response to TLR2 ligand in the presence of NF-κB inhibitor. | |
|
L4 larvae | Immature DC line (JAWS II) | Decreased translocation of p50 NF-κB into the nucleus. | Relative lack of DC activation: TNF-α, TGF-β, IL-6, MCP-1 unchanged, decreased expression of regulatory cytokine (IL-10) and proinflammatory factor (IL-12p70), increased expression of IL-4 (Th2 type). | |
|
Adult stage somatic antigens ( | MLN cells from naive and infected mice | Various changes in p65 and p50 levels in cytoplasm and nucleus nucleus. | Inhibition of apoptosis. |
Flukes impact on NF-κB activity and the main outcomes.
| Parasite | Infection/Life Stage/Antigen | Host/Location/Model | Effect on NF-κB | Outcome |
|---|---|---|---|---|
|
Infected patients | Liver biopsy | Increased p65 presence in hepatic stellate cells’ (HSC) cytoplasm and enhanced translocation to nucleus in infected patients. | Increase in apoptotic HSC number in schistosome-induced fibrosis. | |
|
Infected mice | Mice | Increase of p65 expression in liver. | May promote inflammasome activation. | |
|
Infected mice | Mice | Increased p65 (Ser 276) phosphorylation in colonic tissue. | NF-κB shows significant role during the course of schistosomiasis. | |
|
Secreted extracellular vesicles ( | Colitic mice | Diminished p65 expression in response to | Protective effect of | |
|
Tegumental antigen ( | Mouse bone marrow-derived DCs | Suppressed LPS–induced expression of p65. | ||
|
Native | Mouse bone-marrow derived macrophages; Mice with induced septic shock, | Blocked TLRs from inducing NF-κB activation. | Reduced expression of LPS induced mRNA encoding IL-1β and TNF-α and release of IL-1β, IL-12p70, IL-6, IFN-γ, TNF-α and IL-2. | |
|
| Mouse bone-marrow derived macrophages; Mice with induced septic shock, THP-1 cells, HEK293 cells | Blocked LPS-induced NF-κB activation. | Reduced mRNA expression encoding IL-1β, IL-12p35, IL-12p40, TNF-α, IL-6, NOS-2 | |
|
| Mouse DC and HEK293 cells | r | Induction of IL-6, IL-12p40, and MIP-2, but also prevented IL-17 and IL-23 release. | |
|
| Mouse bone marrow-derived DCs | No change in p65 expression and IκB-α. | Increased release of IL-1β and IL-18 by NLRP3 dependent mechanism. | |
|
Infected mice | Liver cells | Increase in p65 expression and translocation to nucleus. | Possible role of p65 in inhibiting apoptosis. |